

Tanios Bekaii-Saab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10009411/publications.pdf>

Version: 2024-02-01

219
papers

12,590
citations

36203

51
h-index

29081

104
g-index

225
all docs

225
docs citations

225
times ranked

20737
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
2	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
3	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
4	Isocitrate Dehydrogenase-“Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. <i>JCO Precision Oncology</i> , 2022, 6, e2100156.	1.5	10
5	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	0
6	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2149040.	2.8	48
7	Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 437-441.	1.9	5
8	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
9	Frontline therapy for advanced hepatocellular carcinoma: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210861.	1.4	13
10	<i>BRAF</i> -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. <i>Journal of Clinical Oncology</i> , 2022, 40, 2706-2715.	0.8	21
11	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	3.4	6
12	Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 309-316.	1.9	32
13	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. <i>Pancreatology</i> , 2021, 21, 192-199.	0.5	8
14	Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. <i>Cancers</i> , 2021, 13, 954.	1.7	32
15	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 668-675.	1.9	20
16	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	1.9	5
17	ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3641-3648.	3.2	32
18	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10

#	ARTICLE	IF	CITATIONS
19	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G114-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	2.0	16
20	Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data—Reply. <i>JAMA Oncology</i> , 2021, 7, 941.	3.4	0
21	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. <i>European Journal of Cancer</i> , 2021, 151, 14-24.	1.3	18
22	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149
23	Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposure—Safety Analyses in Patients With Metastatic Pancreatic Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, , .	1.3	5
24	Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer—It Is Complicated. <i>JAMA Network Open</i> , 2021, 4, e2134458.	2.8	4
25	Editorial comment on: Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
26	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
27	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
28	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	3.4	124
29	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16
30	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020, 123, 1377-1386.	2.9	4
31	Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. <i>OncImmunity</i> , 2020, 9, 1818437.	2.1	20
32	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
33	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
34	Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. <i>Oncologist</i> , 2020, 25, e1246-e1248.	1.9	3
35	Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. <i>Chinese Clinical Oncology</i> , 2020, 9, 6-6.	0.4	17
36	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	0.5	26

#	ARTICLE	IF	CITATIONS
37	Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. <i>EMBO Molecular Medicine</i> , 2020, 12, e9910.	3.3	21
38	A Rare <i>EGFR</i> – <i>SEPT14</i> Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. <i>Oncologist</i> , 2020, 25, 203-207.	1.9	16
39	The Role of Maintenance Therapy in Metastatic Colorectal Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 937.	3.4	1
40	Improvements in Clinical Outcomes for <i>BRAFV600E</i> -Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
41	Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3117-3125.	3.2	13
42	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 132, 112-121.	1.3	22
43	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	1.8	25
44	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
45	Systemic Treatment for Metastatic or Recurrent Disease. , 2020, , 275-287.		0
46	Precision Medicine in Metastatic Colorectal Cancer—Finding and Hitting the Right Targets. <i>Oncology & Hematology Review</i> , 2020, 16, 36.	0.2	0
47	Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 1068.	1.7	19
48	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
49	Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2019, 7, 17.	1.4	27
50	Watch and Wait in Rectal Cancer: Who’s In and Who’s Out?. <i>Journal of Oncology Practice</i> , 2019, 15, 133-134.	2.5	2
51	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	0.8	301
52	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	3.2	43
53	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , 2019, 15, 1295-1302.	1.1	37
54	Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00098.	1.3	16

#	ARTICLE	IF	CITATIONS
55	A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1174-1179.	1.9	14
56	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	37
57	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	1.0	53
58	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2403-2413.	3.2	40
59	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	0.5	24
60	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. <i>Chinese Clinical Oncology</i> , 2019, 8, S19-S19.	0.4	1
61	A clinical trial protocol paper discussing the BRIGHTER study. <i>Future Oncology</i> , 2018, 14, 901-906.	1.1	18
62	Clinical Trials and Progress in Metastatic Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 349-365.	0.6	64
63	Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. <i>Oncogene</i> , 2018, 37, 3440-3455.	2.6	37
64	Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 140-146.	0.6	5
65	IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. <i>Gut</i> , 2018, 67, 320-332.	6.1	381
66	Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. <i>Small GTPases</i> , 2018, 9, 452-456.	0.7	11
67	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34.	1.9	63
68	Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers. <i>Advances in Radiation Oncology</i> , 2018, 3, 34-41.	0.6	15
69	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	2.3	7
70	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
71	Phase II Study of BGJ398 in Patients With <i>FGFR</i> -Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
72	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1063-1073.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 165-170.	1.0	77
74	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 78-91.	2.0	19
75	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
76	The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 531-534.	0.6	11
77	Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 561-568.	0.6	21
78	Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573.	0.6	45
79	Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , 2017, 123, 1303-1312.	2.0	89
80	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	5.1	322
81	Signaling pathways as therapeutic targets in biliary tract cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 485-498.	1.5	4
82	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. <i>Cancer Research</i> , 2017, 77, 2647-2660.	0.4	113
83	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017, 8, 14755.	5.8	96
84	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	3.4	45
85	Predictors of Pancreatic Cancerâ€™Associated Weight Loss and Nutritional Interventions. <i>Pancreas</i> , 2017, 46, 1152-1157.	0.5	57
86	Secondâ€™line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€™analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	2.0	29
87	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	1.1	16
88	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
89	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 344-356.	1.9	31
90	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	1.0	14

#	ARTICLE	IF	CITATIONS
91	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 489-502.	3.2	46
92	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 75-82.	1.4	46
93	Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. <i>Molecular Cancer Research</i> , 2017, 15, 26-34.	1.5	32
94	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	1.4	10
95	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017, 13, e62-e67.	2.5	1
96	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 445-446.	1.4	0
97	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	0.7	13
98	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
99	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5931-5941.	1.0	4
100	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 673-674.	0.6	0
101	Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016, Volume 6, 21-30.	5.5	8
102	Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. <i>Frontiers in Oncology</i> , 2016, 6, 148.	1.3	33
103	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 614-618.	0.6	14
104	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1528-1534.	2.3	17
105	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. <i>Neoplasia</i> , 2016, 18, 765-774.	2.3	16
106	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 807-814.	1.7	4
107	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016, 33, 48.	1.2	20
108	Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. <i>Annals of Surgical Oncology</i> , 2016, 23, 2281-2286.	0.7	48

#	ARTICLE	IF	CITATIONS
109	Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. <i>Cancer</i> , 2016, 122, 3657-3666.	2.0	41
110	Outcomes of definitive chemoradiation in patients with esophageal cancer. <i>Ecological Management and Restoration</i> , 2016, 30, 1-7.	0.2	8
111	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	2.0	289
112	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	1.0	0
113	Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JAMA Surgery</i> , 2016, 151, e161137.	2.2	365
114	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. <i>Medical Oncology</i> , 2016, 33, 4.	1.2	1
115	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016, 18, 863-868.	1.1	30
116	Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv437.	3.0	20
117	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016, 42, 10-17.	3.4	16
118	Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. <i>Clinical Colorectal Cancer</i> , 2016, 15, e61-e63.	1.0	7
119	Application of next-generation sequencing in gastrointestinal and liver tumors. <i>Cancer Letters</i> , 2016, 374, 187-191.	3.2	14
120	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2565-2574.	3.2	80
121	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	6.3	878
122	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 61-68.	3.2	105
123	Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. <i>Oncotarget</i> , 2016, 7, 5306-5312.	0.8	7
124	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	1.4	14
125	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	1.3	30
126	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1005-1012.	1.1	3

#	ARTICLE	IF	CITATIONS
127	Rectal Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 719-728.	2.3	181
128	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports, 2015, 5, 12122.	1.6	58
129	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines, 2015, 3, 519-543.	2.1	15
130	Selumetinib for the treatment of cancer. Expert Opinion on Investigational Drugs, 2015, 24, 111-123.	1.9	31
131	Therapeutic Advances in Pancreatic Cancer: Miles to Go Before We Sleep. Journal of the National Cancer Institute, 2015, 107, dju439-dju439.	3.0	6
132	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist, 2015, 20, 1132-1139.	1.9	84
133	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunology, Immunotherapy, 2015, 64, 149-159.	2.0	104
134	Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Scientific Reports, 2015, 5, 10867.	1.6	87
135	Second-line outcomes in metastatic colorectal cancer "raising the bar for the high jump rather than the doing the limbo. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 133-143.	0.7	2
136	Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunology, Immunotherapy, 2015, 64, 727-736.	2.0	47
137	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Journal of the National Cancer Institute, 2015, 107, djv274.	3.0	80
138	Maintenance Therapy for Colorectal Cancer: Which Regimen and Which Patients?. Drugs, 2015, 75, 1833-1842.	4.9	3
139	Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Annals of Surgical Oncology, 2015, 22, 1153-1159.	0.7	215
140	CA 19-9 as a Serum Biomarker in Cancer. Biomarkers in Disease, 2015, , 179-201.	0.0	2
141	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. Oncotarget, 2015, 6, 22206-22213.	0.8	7
142	Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget, 2015, 6, 44509-44522.	0.8	15
143	A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. Journal of Gastrointestinal Oncology, 2015, 6, 336-40.	0.6	2
144	Ampullary Cancer: An Overview. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 112-115.	1.8	78

#	ARTICLE	IF	CITATIONS
145	Outcomes in Patients with Obstructive Jaundice from Metastatic Colorectal Cancer and Implications for Management. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2186-2191.	0.9	13
146	Incidence of Minimally Invasive Colorectal Cancer Surgery at National Comprehensive Cancer Network Centers. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju362-dju362.	3.0	48
147	Prostate cancer incidence in males with Lynch syndrome. <i>Genetics in Medicine</i> , 2014, 16, 553-557.	1.1	88
148	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. <i>JAMA Surgery</i> , 2014, 149, 18.	2.2	36
149	Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. <i>Cancer</i> , 2014, 120, 1780-1786.	2.0	23
150	CA 19-9 as a Serum Biomarker in Cancer. , 2014, , 1-19.		0
151	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. <i>Pancreas</i> , 2014, 43, 343-349.	0.5	8
152	Optimal Management of Gastric Cancer. <i>Annals of Surgery</i> , 2014, 259, 102-108.	2.1	48
153	The Addition of Radiation to Chemotherapy does not Improve Outcome When Compared to Chemotherapy in the Treatment of Resected Pancreas Cancer: The Results of a Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2014, 21, 862-867.	0.7	5
154	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. <i>Investigational New Drugs</i> , 2014, 32, 113-122.	1.2	42
155	Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 9-34.	2.0	27
156	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1123-1130.	2.3	37
157	Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 235-243.	2.3	14
158	Moving Forward With Expanding to an "All-RAS" Mutational Analysis in Metastatic Colorectal Cancer: Beyond KRAS Mutations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 299-300.	2.3	5
159	Colon Cancer, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1028-1059.	2.3	192
160	Pain, depression, and fatigue: Loneliness as a longitudinal risk factor.. <i>Health Psychology</i> , 2014, 33, 948-957.	1.3	234
161	Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. <i>Cancer</i> , 2013, 119, 285-292.	2.0	103
162	A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. <i>Cancer</i> , 2013, 119, 2692-2700.	2.0	168

#	ARTICLE	IF	CITATIONS
163	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1499-1506.	1.1	51
164	Peptide Vaccines and Peptidomimetics of EGFR (HER-1) Ligand Binding Domain Inhibit Cancer Cell Growth In Vitro and In Vivo. <i>Journal of Immunology</i> , 2013, 191, 217-227.	0.4	39
165	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 347-357e1.	0.2	42
166	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 685-695.	1.2	26
167	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. <i>Surgery</i> , 2013, 154, 1100-1109.	1.0	14
168	A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2013, 79, 27-32.	0.9	4
169	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 533-541.	0.7	12
170	<i>KRAS</i> mutations: impact on treatment outcome. <i>Colorectal Cancer</i> , 2013, 2, 525-534.	0.8	0
171	FOLFIRINOX in Locally Advanced Pancreas Adenocarcinoma: Back to the Future?. <i>Oncologist</i> , 2013, 18, 487-489.	1.9	4
172	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner. <i>Cancer Research</i> , 2013, 73, 3007-3018.	0.4	340
173	Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 298-307.	2.3	17
174	Metastatic Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 141-152.	2.3	130
175	Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-18-S-27.	2.3	9
176	A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 6-6.	1.1	5
177	Localized Colon Cancer, Version 3.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 519-528.	2.3	81
178	Integrating anti-EGFR therapies in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 285-98.	0.6	20
179	HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib. <i>Oncology</i> , 2012, 82, 175-179.	0.9	96
180	Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 104-106.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Anal Carcinoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 449-454.	2.3	67
182	Rectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1528-1564.	2.3	138
183	A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, e475-e481.	0.4	17
184	Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. Clinical Colorectal Cancer, 2012, 11, 195-199.	1.0	26
185	Adjuvant Therapy Following Curative Resection of Metastases. Current Colorectal Cancer Reports, 2012, 8, 217-224.	1.0	0
186	Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Medical Oncology, 2012, 29, 3101-3107.	1.2	23
187	Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study. Oncology, 2012, 83, 135-140.	0.9	1
188	Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series. Photomedicine and Laser Surgery, 2012, 30, 668-671.	2.1	3
189	O-0002 A Phase 2 Adjuvant Trial of GI-4000 Plus Gemcitabine vs. Gemcitabine Alone in Ras+ Patients with Resected Pancreas Cancer: R1 Subgroup Analysis. Annals of Oncology, 2012, 23, iv5.	0.6	5
190	Fractionated radioimmunotherapy with ⁹⁰ Y-εclivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. Cancer, 2012, 118, 5497-5506.	2.0	79
191	Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer, 2012, 118, 6243-6252.	2.0	20
192	A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 629-638.	1.2	24
193	STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH+/CD133+ stem cell-like human colon cancer cells. Biochemical and Biophysical Research Communications, 2011, 416, 246-251.	1.0	112
194	Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Investigational New Drugs, 2011, 29, 347-351.	1.2	19
195	A phase I study of topotecan and gemcitabine in advanced solid tumors. Investigational New Drugs, 2011, 29, 1390-1394.	1.2	0
196	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunology, Immunotherapy, 2011, 60, 1269-1279.	2.0	134
197	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTx) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2011, 67, 511-517.	1.1	8
198	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. Journal of Clinical Oncology, 2011, 29, 2357-2363.	0.8	272

#	ARTICLE	IF	CITATIONS
199	Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1238-1290.	2.3	52
200	Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal of Thoracic Oncology, 2010, 5, 713-718.	0.5	14
201	Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 378-409.	2.3	140
202	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 65, 319-324.	1.1	5
203	A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology, 2010, 65, 863-869.	1.1	0
204	A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 151-158.	1.1	12
205	Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 1019-1029.	1.1	19
206	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). Oncologist, 2010, 15, 1310-1319.	1.9	58
207	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. Clinical Cancer Research, 2009, 15, 5895-5901.	3.2	101
208	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. Clinical Colorectal Cancer, 2009, 8, 135-140.	1.0	4
209	Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anti-Cancer Drugs, 2009, 20, 444-449.	0.7	57
210	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report. Journal of Hematology and Oncology, 2008, 1, 18.	6.9	50
211	An Update on Biochemotherapy of Advanced Gastric and Gastroesophageal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 895-900.	2.3	8
212	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer, 2006, 6, 278.	1.1	46
213	Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers in Surgery and Medicine, 2006, 38, 881-889.	1.1	36
214	Esophageal Cancer Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 328.	2.3	25
215	Gastric Cancer Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 350.	2.3	27
216	Hepatobiliary Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 728.	2.3	14

#	ARTICLE	IF	CITATIONS
217	UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 656-665.	1.3	105
218	Late Relapse of Ovarian Dysgerminoma: Case Report and Literature Review. <i>Gynecologic Oncology</i> , 1999, 72, 111-112.	0.6	11
219	ZEBRA: An IRCI/ACCRI (RU021502I) Multicenter Phase II Study of Pembrolizumab in Patients With Advanced Small Bowel Adenocarcinoma (SBA). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0